Ethylmorphine
Viewing r1 — May 10, 2026
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Ethylmorphine (codethyline) — also known as dionine — is a semi-synthetic opioid of the morphinan class. It is a close structural analog of codeine, functioning as a prodrug of morphine.[1] Ethylmorphine is a µ-opioid receptor agonist with weak direct binding affinity,[2] producing its effects primarily through hepatic conversion to morphine.[3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, codeine, oxycodone +3 moremorphine, codeine, oxycodone, hydrocodone, heroin, all mu-opioid agonists show less
Synthesized by Merck in Germany in 1884,[1] ethylmorphine entered clinical use as an ophthalmic analgesic under the brand name Dionine. It found its primary market as a prescription cough suppressant in France and Norway from the 1950s onward, though it was never approved in the United States. It remains available by prescription in several European countries and is controlled internationally under the 1961 Single Convention on Narcotic Drugs.
Subjective effects include analgesia, sedation, euphoria, and anxiolysis. The experience follows the μ-opioid pattern — a gradual onset of warmth, bodily heaviness, and quiet contentment — though intensity is capped by the metabolic bottleneck of conversion to morphine, producing a gentler ceiling than direct-acting opioids. Nausea, constipation, and respiratory slowing are characteristic unsought effects.
Ethylmorphine produces physical dependence with chronic use, and a fatal blood concentration sits approximately nine times the level found in impaired drivers.[4][5] Response varies dramatically with CYP2D6 genetic status — the same dose can produce minimal effects in one person and dangerous morphine levels in another[6] — and combination with alcohol creates a dual-mechanism lethal risk.[7] The evidence base rests on pharmacokinetic studies and forensic reports rather than controlled trials, leaving significant gaps.
History[edit]
Discovery
Ethylmorphine was first synthesized by Merck in Germany in 1884,[1] during a wave of semi-synthetic opioid development that also produced heroin. The compound was created as a weaker morphine alternative, with ethylation of morphine's 3-hydroxyl group intended to reduce potency while preserving analgesic and antitussive properties.[1] Its earliest clinical application was in ophthalmology — a 1904 paper in the British Medical Journal described its use as an eye analgesic under the brand name Dionine.[8]
Clinical adoption
Ethylmorphine's modern pharmaceutical life began in 1953 when Houde launched it as a cough suppressant in France under the name Codethyline, followed by Norway and Spain in 1960.[1] In Norway, it became the active ingredient of Cosylan, a prescription cough syrup that remained in clinical use for decades.[3][9] It was never approved for use in the United States.[1]
Scheduling and abuse
International control came under the 1961 Single Convention on Narcotic Drugs, which placed ethylmorphine in Schedule II.[1] Despite its positioning as a mild opioid, forensic evidence documents patterns of abuse — hair analysis in a fatal overdose case revealed switching from heroin to ethylmorphine,[4] and Swedish impaired-driver data confirmed its use as an intoxicant, with 63 of 2,573 samples testing positive.[5]
The name Dionine — ethylmorphine's original brand — derives from its early marketing as an ophthalmic preparation in the early 1900s. The alternate name codethyline reflects its structural kinship with codeine (3-O-methyl morphine), positioning it as the ethyl structural analog in the same chemical series. Neither name carries significant cultural resonance outside pharmaceutical history; ethylmorphine has never acquired the street identity or subcultural mythology of its more potent relatives morphine and heroin.
Chemistry[edit]
Structural class
Ethylmorphine belongs to the morphinan chemical class. It is the 3-O-ethyl ether of morphine — structurally identical to morphine except that the 3-hydroxyl group carries an ethyl (–OCH₂CH₃) substituent.[1] This places it in a direct series with codeine (3-O-methyl morphine), differing by a single methylene unit in the alkoxy chain.
| Molecular formula | C₁₉H₂₃NO₃ |
| Molecular weight | 313.4 g/mol |
The morphinan scaffold comprises five fused rings: a benzene ring, two partially saturated cyclohexane rings, a piperidine ring, and a dihydrofuran ring bridging via the 4,5-epoxy oxygen.[10] The 3-ethoxy group sits on the aromatic ring, the 6-hydroxyl on ring C, and a double bond occupies the 7,8-position.
Stereochemistry
Ethylmorphine retains the five chirality centers of natural morphine.[10] Only the natural (–)-enantiomer possesses opioid receptor activity — a stereochemical requirement conserved across all pharmacologically active morphinans.
Structure-activity relationships
The 3-position alkoxy group is the key structural variable in the morphine–codeine–ethylmorphine series. Increasing alkyl chain length at this position progressively reduces direct μ-opioid binding affinity: morphine (free hydroxyl) binds most strongly, followed by codeine (methyl), then ethylmorphine (ethyl).[2] This same modification converts each compound into a prodrug requiring liver metabolism to regenerate the active 3-hydroxyl morphine scaffold.
Physical properties
No published melting point or solubility data for ethylmorphine free base were identified. The hydrochloride salt is the pharmaceutical form used in marketed products.[9] Oxidation to ethylmorphine-N-oxide during storage has been documented, indicating sensitivity to oxidative degradation.[9]
Pharmacology[edit]
Mechanism of action
Ethylmorphine functions primarily as a prodrug — its opioid effects are not produced by the parent compound but by morphine, generated through liver metabolism.[1][3] The parent compound binds mu-opioid receptors far more weakly than either morphine or codeine, with binding strength declining as the 3-position ether chain grows longer.[2]
Once formed, morphine activates mu-opioid receptors throughout the central nervous system, producing the full range of opioid effects: pain suppression via descending inhibitory pathways, euphoria via mesolimbic dopamine release, cough suppression, sedation, and respiratory depression.[11][12]
Independently of its opioid activity, ethylmorphine blocks nerve impulse conduction through a mechanism unrelated to opioid receptors — an effect not reversed by naloxone.[13][14] This local anesthetic-like action occurs only at concentrations far above those reached in the bloodstream and is relevant only to topical formulations such as the historical Dionine eye drops.
Pharmacokinetics
Ethylmorphine undergoes extensive first-pass liver metabolism through three pathways. The pharmacologically critical pathway converts ethylmorphine to morphine, which is then further processed to both inactive and active metabolites.[6][3] A second pathway produces norethylmorphine,[7][15] and a third produces ethylmorphine-6-glucuronide — the most abundant metabolite found in urine.[3]
After a single oral dose of cough syrup, peak blood levels occur at approximately 45 minutes, with a half-life of about 2 hours and 77% recovery in urine over 48 hours.[3] Tablet formulations peak later, at roughly 2 hours.[16]
The most clinically significant variable is genetic variation in the liver enzyme responsible for morphine formation. Poor metabolizers convert approximately 3% of a dose to morphine, while extensive metabolizers convert roughly 11% — a ninefold range of variation.[6] Ethylmorphine produces proportionally more morphine than an equivalent dose of codeine regardless of metabolizer status.[6]
Neuroscience[edit]
Where it acts
Ethylmorphine's central effects are those of its active metabolite morphine, acting on three primary neural circuits. In the mesolimbic mesolimbic pathway, μ-opioid activation in the ventral tegmental area releases dopamine in the nucleus accumbens — the mechanism behind opioid euphoria and abuse liability.[11] In descending pain pathways, morphine activates mu-receptors in the periaqueductal gray, triggering a cascade that suppresses pain signals at the spinal level.[11] In brainstem respiratory centers, mu-receptor activation depresses breathing in a dose-dependent manner — the primary mechanism of opioid-related death.[11]
Why it matters
Chronic mu-opioid agonist exposure disrupts the brain's endogenous opioid system. Exogenous morphine displaces the body's natural opioid peptides and, over time, suppresses their production. When the drug is removed, the endogenous system cannot immediately compensate — producing the withdrawal of autonomic instability, pain hypersensitivity, and distress.
At the cellular level, tolerance involves receptor desensitization and internalization, while adaptive changes in cellular signaling produce the noradrenergic hyperactivity that drives physical withdrawal symptoms.[11]
CYP2D6 ultrarapid metabolizer risk: Individuals carrying gene duplications for the enzyme that converts ethylmorphine to morphine (1–10% of some populations) may produce dangerously high morphine levels from standard doses. Fatal outcomes have been documented for codeine in this population, but equivalent investigation for ethylmorphine has not been conducted.citation needed
Subjective Effects[edit]
The experiential character of ethylmorphine is shaped by its prodrug nature: effects emerge gradually as the liver converts the parent compound to morphine, producing a gentler onset than direct-acting opioids. The warmth, bodily heaviness, and anxiolysis of μ-opioid agonism predominate. At higher doses, sedation deepens and euphoria becomes more pronounced, though the metabolic conversion bottleneck imposes a lower intensity ceiling than morphine itself.
Relative to codeine, ethylmorphine produces modestly greater opioid character per milligram, positioning it as an intermediate between codeine and low-dose morphine. The qualitative experience is indistinguishable from other mu-agonist prodrugs; the distinguishing feature is the pharmacogenomic unpredictability of response magnitude — CYP2D6 phenotype determines whether a given dose produces minimal or significant effects.
Effect Grid
Clear mu-opioid agonist effects emerge — moderate analgesia, noticeable sedation, and a warm euphoric contentment. Anxiety suppression is pronounced. Pupil constriction is visible and consistent. The antitussive ceiling is reached within this range.
Bodily heaviness and muscle relaxation are prominent. Nausea is possible, particularly in opioid-naive users. Constipation onset begins. Mild respiratory slowing occurs but is typically not subjectively distressing at this level. A body high characterized by diffuse warmth and spontaneous pleasant sensations is common.
Cognitive effects include thought deceleration, focus suppression, and mild motor control impairment. This range straddles the upper therapeutic boundary — doses above 50 mg exceed published therapeutic recommendations.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing suppression
Body high · Constipation · Pain suppression · Bodily heaviness · Breathing alteration · Physical fatigue · Tactile euphoria · Dizziness · Nausea · Spontaneous body sensations · Appetite suppression · Dry mouth · Sexual arousal suppression · Vomiting · Yawning · Excessive sweating · Temperature dysregulation · Heart rate perception changes · Involuntary body movements · Nystagmus (eye wobbles) · Bodily dissociation
Bodily heaviness · Breathing alteration · Physical fatigue · Tactile euphoria · Dizziness · Nausea · Spontaneous body sensations · Appetite suppression · Dry mouth · Sexual arousal suppression · Vomiting · Yawning · Excessive sweating · Heart rate perception changes · Involuntary body movements · Nystagmus (eye wobbles) · Bodily dissociation
Thought deceleration · Analysis suppression · Focus suppression · Information processing suppression · Creativity suppression · Memory suppression · Motivation suppression · Confusion · Language suppression · Thought disorganization · Cognitive dysphoria · Amnesia
Information processing suppression · Creativity suppression · Memory suppression · Motivation suppression · Confusion · Language suppression · Thought disorganization · Cognitive dysphoria
Disinhibition · Depersonalization · Derealization · Cognitive disconnection
Timeline
Initial absorption begins; effects emerge as CYP2D6 converts ethylmorphine to morphine. Faint warmth and mild anxiolysis are the first signals. Onset timing varies with formulation — syrup reaches Tmax in ~45 min, tablets in ~2.
Progressive deepening of analgesia, sedation, and euphoria as morphine levels build in the CNS. Bodily heaviness and muscle relaxation become noticeable. Pupil constriction begins.
Maximum opioid effects — analgesia, euphoria, sedation, and pupil constriction are fully established. Respiratory depression is dose-dependent and most significant here. Nausea, if it occurs, typically peaks during this phase.
Gradual decline as ethylmorphine (t½ = 2h) and morphine are cleared. Sedation typically outlasts euphoria. Analgesia fades progressively.
Residual sedation and mild warmth linger. Constipation may persist for hours. Opiate immunoassay screens remain positive for 24+ hours post-dose.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 1.5 weeks
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- morphine · codeine · oxycodone
Toxicity
Acute toxicity
No established lethal dose exists for ethylmorphine in any species.safety citation needed One unverified source suggests an approximate lethal oral dose of 500 mg in humans.[8]safety citation needed
The sole published fatal overdose recorded a blood concentration of 488 ng/mL — approximately nine times the mean level found in impaired drivers (55 ng/mL).[4][5] Hair analysis in this case revealed a history of heroin use followed by a switch to ethylmorphine.[4]
Respiratory depression is the primary mechanism of opioid-related death, driven by morphine acting on brainstem respiratory centers.[11] This risk is dose-dependent and markedly increased by concurrent use of other depressants.[11]
Liver toxicity
Ethylmorphine depletes the liver's protective glutathione stores in animal models, an effect triggered centrally through μ-opioid activation.[17] This depletion increases vulnerability to liver-toxic substances, particularly paracetamol (acetaminophen).[17] Co-administration of ethylmorphine with paracetamol may elevate liver damage risk beyond what either substance produces alone.
Psychological risks
No controlled studies on ethylmorphine's psychological effects have been published. By class inference from mu-opioid pharmacology:
- Cognitive impairment: Attention, reaction time, and decision-making are impaired in a dose-dependent manner. Impaired-driving data confirm psychomotor effects at therapeutic concentrations.[5]
- Mood disturbance: The rewarding properties of opioids create a cycle of withdrawal-related low mood that can worsen pre-existing depression during cessation.
- Increased pain sensitivity: Chronic opioid use can paradoxically heighten pain perception, a phenomenon documented for morphine but not specifically studied for ethylmorphine.inferred
Tolerance and dependence
Tolerance develops with repeated use, driven by the same receptor desensitization that characterizes all mu-opioid agonists.[11] No ethylmorphine-specific tolerance timeline has been published; available estimates are generic opioid class approximations without substance-specific support.inferred
Cross-tolerance is established with all mu-opioid agonists, including morphine, codeine, oxycodone, and other morphinan opioids.[12]
Ethylmorphine carries significant abuse liability, documented by forensic evidence: switching from heroin to ethylmorphine,[4] use as an intoxicant in impaired driving,[5] and controlled-substance classification across major jurisdictions.[1] Physical withdrawal — including tearing, runny nose, muscle pain, insomnia, anxiety, and digestive disturbance — is expected by class inference.inferred
Drug interactions
Combination of ethylmorphine with other depressants — particularly alcohol, GHB/GBL, benzodiazepines, or other opioids — carries a risk of fatal respiratory depression. The ethylmorphine–alcohol interaction operates through dual mechanisms, making lethality risk particularly difficult to predict.Alcohol is the most critical interaction. Ethanol inhibits all three metabolic pathways of ethylmorphine: morphine formation reduced 44%, N-demethylation reduced 35%, and glucuronidation reduced 30–60% at physiologically relevant concentrations.[7] Total elimination slows by 38%.[7] This pharmacokinetic effect — raising parent drug levels — compounds the pharmacodynamic synergism of additive respiratory depression, creating a dual-mechanism lethal risk.
GHB and GBL produce additive respiratory and central nervous system depression when combined with opioids. GHB alone can cause death via cardiorespiratory collapse at high plasma concentrations;[18] GBL converts to GHB within approximately one minute of ingestion.[18]
Tramadol adds opioid respiratory depression and additionally lowers seizure threshold[19][20] and carries serotonin syndrome risk in polypharmacy contexts.[19]
CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) reduce conversion of ethylmorphine to morphine, potentially decreasing analgesic effect while altering the metabolic profile unpredictably.[8]
CYP3A4 inducers (barbiturates, rifampin, carbamazepine) accelerate an alternate metabolic pathway, potentially reducing ethylmorphine's effectiveness.[8]
Paracetamol (acetaminophen): Ethylmorphine depletes liver glutathione stores,[17] increasing vulnerability to paracetamol-induced liver damage.
Contraindications
Breathing difficulties (absolute): Asthma, chronic obstructive pulmonary disease, and other conditions involving compromised lung function are absolute contraindications due to opioid respiratory depression.[1][8]
Concurrent depressant use (absolute): Co-administration with alcohol, benzodiazepines, barbiturates, GHB/GBL, or other opioids is contraindicated due to additive respiratory depression.[7]
Children (absolute): Ethylmorphine is contraindicated in children under approximately 8 years of age.[8] The risk is amplified in pediatric ultrarapid metabolizers, who may convert ethylmorphine to morphine at dangerous rates.
Intravenous use (absolute): IV administration is contraindicated due to the risk of dangerous histamine release.[8]
Ultrarapid metabolizer status (relative): Individuals who metabolize the drug unusually quickly are at elevated risk of morphine toxicity from standard doses — established by analogy with codeine safety data.[12]inferred
Liver impairment (relative): Pre-existing liver disease may alter both the effectiveness and toxicity of ethylmorphine, given its dependence on liver metabolism and its glutathione-depleting effects.[17]
Driving and machinery operation: Psychomotor impairment is documented at therapeutic and above-therapeutic concentrations.[5]
Harm Reduction[edit]
Forms & Identification
Ethylmorphine circulates almost exclusively as manufactured pharmaceutical products — primarily cough syrups and tablets — rather than as raw powder or pressed pills from unregulated sources. Identification is typically a matter of verifying that a commercial product is genuine and unexpired rather than testing an unknown substance.
The primary identification risk is confusion with other opioid preparations. Pharmaceutical ethylmorphine products are region-specific (Cosylan in Norway, Codethyline formulations in France) and may be unfamiliar outside their home markets. Verify the product name, manufacturer, and active ingredient against known formulations before use.
Set & Setting
Opioid effects are modulated less by psychological set and environmental setting than psychedelics or empathogens. Nevertheless, using ethylmorphine in a safe, comfortable environment reduces risk — sedation and psychomotor impairment increase the danger of falls, accidents, and decision impairment. Avoid situations requiring alertness, coordination, or driving.
Guidelines
- Use only pharmaceutical-grade preparations from verified sources.
- Start with the lowest available dose, particularly if CYP2D6 metabolizer status is unknown — individual conversion to morphine varies ninefold.
- Do not combine with alcohol, benzodiazepines, GHB/GBL, or other opioids under any circumstances.
- Do not combine with paracetamol (acetaminophen) due to shared liver toxicity.
- Allow adequate time between doses — the 2-hour half-life means effects from repeated dosing accumulate.
- Do not use alone, particularly at higher doses or during initial use when individual sensitivity is unknown.
- Avoid driving or operating machinery.
Aftercare & Integration
Following opioid use, allow the body adequate recovery time. Mild rebound effect discomfort, irritability, or low mood may occur as the opioid effects wear off — these typically resolve within 24–48 hours after occasional use.
Stay hydrated and eat light meals, as opioids commonly suppress appetite and slow digestion. Constipation may persist for a day or more after use. If opioid use was motivated by emotional distress or pain avoidance, consider whether the underlying issue warrants professional support before repeating use.
Recovery & Support
Ethylmorphine, like all μ-opioid agonists, produces physical dependence with regular use. Withdrawal symptoms — muscle aches, insomnia, anxiety, runny nose, sweating, and digestive disturbance — typically begin within hours of the last dose and peak at 48–72 hours.
Medical supervision during withdrawal is recommended, as healthcare providers can manage symptoms with appropriate medications. Abrupt cessation after prolonged use is uncomfortable but rarely life-threatening, unlike withdrawal from alcohol or benzodiazepines.
For ongoing support, opioid-specific treatment options include medication-assisted treatment with buprenorphine or methadone, which stabilize opioid receptor activity and reduce cravings. Peer support communities, counseling, and addiction medicine specialists can be accessed through national helplines and local treatment directories.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing has slowed, become shallow, or stopped
- Lips, fingertips, or skin turning blue or grey
- Person is unresponsive to voice or physical stimulation
- Gurgling, choking, or snoring sounds in an unconscious person
Immediate steps:
- 1. Call emergency services immediately.
- 2. If naloxone is available, administer it — naloxone reverses opioid respiratory depression. A second dose may be needed after 2–3 minutes if breathing does not improve.
- 3. Place the person in the recovery position (on their side) to prevent choking.
- 4. Stay with the person until help arrives — naloxone wears off faster than most opioids, and respiratory depression may return.
- 5. Do NOT induce vomiting in an unconscious person.
What to tell the dispatcher: Describe the substance taken (ethylmorphine / opioid cough medicine), the amount if known, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Naloxone (Narcan) reverses opioid respiratory depression and is the specific antidote. It is available without prescription in many jurisdictions.
Legal Status[edit]
Ethylmorphine is controlled internationally under the 1961 United Nations Single Convention on Narcotic Drugs, placed in Schedule II, with dilute preparations (≤100 mg per dosage unit, ≤2.5% concentration) listed in Schedule III.[1] Despite international scheduling, it remains available by prescription as a cough suppressant in several countries. It has never been approved for clinical use in the United States.[1]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (pure); Schedule III/V (combinations) | Pure ethylmorphine is Schedule II. Combinations with non-narcotic ingredients at ≤100 mg/100 mL or ≤15 mg/dosage unit are Schedule III. No US-marketed products exist[1] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled as a Class B substance[1] |
| Canada | Schedule I (CDSA) | Highest domestic scheduling level[1] |
| Australia | Schedule 8 (Drugs of Dependence) | Lower-concentration combination products may fall under Schedule 2 or 4 |
| Germany | Prescription-only; higher doses Anlage II (BtMG) | Standard doses require prescription; higher-dose formulations controlled under the Betäubungsmittelgesetz[1] |
| Brazil | Class A2 narcotic | Classified as a narcotic substance[1] |
| France | Prescription (Codethyline) | First market for modern antitussive formulation (1953); available by prescription[1] |
| Norway | Prescription (Class B / Rx) | Marketed as Cosylan (1.7 mg/mL ethylmorphine HCl) for antitussive use[3] |
Forensic considerations
Ethylmorphine is metabolized to morphine in the body. Following ingestion, urine tests positive for morphine on standard opiate immunoassays — 100% of subjects tested positive within 24 hours of a single oral dose of 25–50 mg.[21] The morphine-to-ethylmorphine ratio exceeds 1.0 by 12–24 hours,[21] meaning a positive morphine test may originate from ethylmorphine, codeine, heroin, or direct morphine use. Norethylmorphine is the recommended additional marker to identify ethylmorphine as the source.[3]
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6] ^abcdHedenmalm K, Sundgren M, Granberg K, Spigset O, Dahlqvist R (1997) Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity — Therapeutic Drug Monitoring PMID:9421105